Stockscreener 앱 받기
82.27
0.42%
-0.35
시간 외 거래:
82.66
0.39
+0.47%
Celcuity Inc 주식(CELC)의 최신 뉴스
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Celcuity Inc (CELC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celcuity Inc (CELC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Investors to Connect - ACCESS Newswire
Celcuity Inc (CELC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celcuity Inc (CELC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CELC6137628 Bond Risk Profile - TradingView
Celcuity Inc. Revenue Breakdown – NASDAQ:CELC - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ETFs Investing in Celcuity Inc. Stocks - TradingView
Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality - Kavout | AI
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Celcuity Inc. (CELC) Investor Outlook: Analyzing an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Celcuity Inc (CELC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Celcuity's Revtorpyk approval fuels blockbuster expectations - S&P Global
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
Price to sales forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Celcuity faces securities fraud probe after FDA delays breast cancer drug launch, shares drop 17.6%. - Pluang
2026-07-23 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Investors to Learn More About the Investigation | NDAQ:CELC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Stockholders to Connect - ACCESS Newswire
With FDA approval, Celcuity sees big future for its new breast cancer drug - Star Tribune
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win - Yahoo Finance
CELC stock clocks best day in about 2 months on first FDA approval for cancer drug - MSN
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer - Sahm
Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug - MSN
Kirby McInerney LLP investigates Celcuity for p... - Pluang
CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval - webull.com
Celcuity (CELC) Receives a Buy from Leerink Partners - The Globe and Mail
Precision Trading with Celcuity Inc. (CELC) Risk Zones - Stock Traders Daily
Celcuity got its cancer drug approved. Then its stock dipped - Endpoints News
Form 4 Celcuity LLC For: 16 July By Investing.com - Investing.com Nigeria
Form 13D/A Celcuity Inc. For: 16 July By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc.CELC - PR Newswire
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 - Investing.com Nigeria
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 By Investing.com - Investing.com South Africa
Form 13D/A Celcuity Inc. For: 16 July - Investing.com India
Craig-Hallum Sticks to Their Buy Rating for Celcuity (CELC) - The Globe and Mail
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178 - Moomoo
Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations - Kavout | AI
Celcuity (CELC) Experiences Significant Decline - GuruFocus
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer - MedCity News
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Classic Rock 103.5 WIMZ
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits - Investor's Business Daily
US FDA approves Celcuity's breast cancer drug - MSN
Stifel reiterates Celcuity stock rating on FDA approval of Revtorpyk By Investing.com - Investing.com South Africa
Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC) - Seeking Alpha
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval - MSN
Celcuity gains FDA approval for closely watched breast cancer drug - BioPharma Dive
Celcuity’s Revtorpyk wins FDA nod in breast cancer - BioWorld News
1.97%
0.83%
자본화:
|
볼륨(24시간):